請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37904完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳青周(Ching-Chow Chen) | |
| dc.contributor.author | Pei-Jie Lin | en |
| dc.contributor.author | 林沛潔 | zh_TW |
| dc.date.accessioned | 2021-06-13T15:50:16Z | - |
| dc.date.available | 2013-08-13 | |
| dc.date.copyright | 2008-08-13 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-06-26 | |
| dc.identifier.citation | Armeanu, S., M. Bitzer, et al. (2005). 'Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.' Cancer Res 65(14): 6321-9.
Azuma, T., T. Takahashi, et al. (2003). 'Human CD4+ CD25+ regulatory T cells suppress NKT cell functions.' Cancer Res 63(15): 4516-20. Baylin, S. B. and J. E. Ohm (2006). 'Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?' Nat Rev Cancer 6(2): 107-16. Blagosklonny, M. V., R. Robey, et al. (2002). 'Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.' Mol Cancer Ther 1(11): 937-41. Bolden, J. E., M. J. Peart, et al. (2006). 'Anticancer activities of histone deacetylase inhibitors.' Nat Rev Drug Discov 5(9): 769-84. Bolden, J. E., M. J. Peart, et al. (2006). 'Anticancer activities of histone deacetylase inhibitors.' Nat Rev Drug Discov 5(9): 769-84. Bonish, B., D. Jullien, et al. (2000). 'Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells.' J Immunol 165(7): 4076-85. Boyault, C., K. Sadoul, et al. (2007). 'HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination.' Oncogene 26(37): 5468-76. Breslow, R., B. Jursic, et al. (1991). 'Potent cytodifferentiating agents related to hexamethylenebisacetamide.' Proc Natl Acad Sci U S A 88(13): 5542-6. Brigl, M. and M. B. Brenner (2004). 'CD1: antigen presentation and T cell function.' Annu Rev Immunol 22: 817-90. Brigl, M., L. Bry, et al. (2003). 'Mechanism of CD1d-restricted natural killer T cell activation during microbial infection.' Nat Immunol 4(12): 1230-7. Brutkiewicz, R. R. (2006). 'CD1d ligands: the good, the bad, and the ugly.' J Immunol 177(2): 769-75. Brutkiewicz, R. R., C. A. Willard, et al. (2007). 'Protein kinase C delta is a critical regulator of CD1d-mediated antigen presentation.' Eur J Immunol 37(9): 2390-5. Chang, Y. J., J. R. Huang, et al. (2007). 'Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.' Proc Natl Acad Sci U S A 104(25): 10299-304. Chen, L., W. Fischle, et al. (2001). 'Duration of nuclear NF-kappaB action regulated by reversible acetylation.' Science 293(5535): 1653-7. Chen, Q. and A. C. Ross (2007). 'Retinoic acid regulates CD1d gene expression at the transcriptional level in human and rodent monocytic cells.' Exp Biol Med (Maywood) 232(4): 488-94. Chen, Q. Y. and N. Jackson (2004). 'Human CD1D gene has TATA boxless dual promoters: an SP1-binding element determines the function of the proximal promoter.' J Immunol 172(9): 5512-21. Colgan, S. P., V. M. Morales, et al. (1996). 'IFN-gamma modulates CD1d surface expression on intestinal epithelia.' Am J Physiol 271(1 Pt 1): C276-83. Crowe, N. Y., M. J. Smyth, et al. (2002). 'A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.' J Exp Med 196(1): 119-27. De Libero, G. and L. Mori (2005). 'Recognition of lipid antigens by T cells.' Nat Rev Immunol 5(6): 485-96. de Ruijter, A. J., A. H. van Gennip, et al. (2003). 'Histone deacetylases (HDACs): characterization of the classical HDAC family.' Biochem J 370(Pt 3): 737-49. Deroanne, C. F., K. Bonjean, et al. (2002). 'Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling.' Oncogene 21(3): 427-36. Dhodapkar, M. V., J. Krasovsky, et al. (2003). 'Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.' J Exp Med 198(11): 1753-7. Dokmanovic, M. and P. A. Marks (2005). 'Prospects: histone deacetylase inhibitors.' J Cell Biochem 96(2): 293-304. Drummond, D. C., C. O. Noble, et al. (2005). 'Clinical development of histone deacetylase inhibitors as anticancer agents.' Annu Rev Pharmacol Toxicol 45: 495-528. Enya, K., H. Hayashi, et al. (2008). 'The interaction with Sp1 and reduction in the activity of histone deacetylase 1 are critical for the constitutive gene expression of IL-1 alpha in human melanoma cells.' J Leukoc Biol 83(1): 190-9. Epping, M. T., L. Wang, et al. (2007). 'A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors.' Proc Natl Acad Sci U S A 104(45): 17777-82. Exley, M., J. Garcia, et al. (2000). 'CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes.' Immunology 100(1): 37-47. Fujii, S., K. Liu, et al. (2004). 'The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation.' J Exp Med 199(12): 1607-18. Fujii, S., K. Shimizu, et al. (2003). 'Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes.' Br J Haematol 122(4): 617-22. Fujii, S., K. Shimizu, et al. (2003). 'Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.' J Exp Med 198(2): 267-79. Furumai, R., A. Matsuyama, et al. (2002). 'FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.' Cancer Res 62(17): 4916-21. Gabrielli, B. G., R. W. Johnstone, et al. (2002). 'Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress.' Curr Cancer Drug Targets 2(4): 337-53. Galm, O., J. G. Herman, et al. (2006). 'The fundamental role of epigenetics in hematopoietic malignancies.' Blood Rev 20(1): 1-13. Gao, L., M. A. Cueto, et al. (2002). 'Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.' J Biol Chem 277(28): 25748-55. Gardiner-Garden, M. and M. Frommer (1987). 'CpG islands in vertebrate genomes.' J Mol Biol 196(2): 261-82. Geng, Y., P. Laslo, et al. (2005). 'Transcriptional regulation of CD1D1 by Ets family transcription factors.' J Immunol 175(2): 1022-9. Girardi, M., E. Glusac, et al. (2003). 'The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer.' J Exp Med 198(5): 747-55. Girardi, M., D. E. Oppenheim, et al. (2001). 'Regulation of cutaneous malignancy by gammadelta T cells.' Science 294(5542): 605-9. Godfrey, D. I. and S. P. Berzins (2007). 'Control points in NKT-cell development.' Nat Rev Immunol 7(7): 505-18. Godfrey, D. I., H. R. MacDonald, et al. (2004). 'NKT cells: what's in a name?' Nat Rev Immunol 4(3): 231-7. Gomes, A. Q., D. V. Correia, et al. (2007). 'Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance.' EMBO Rep 8(11): 1024-30. Grunstein, M. (1990). 'Nucleosomes: regulators of transcription.' Trends Genet 6(12): 395-400. Gumperz, J. E., C. Roy, et al. (2000). 'Murine CD1d-restricted T cell recognition of cellular lipids.' Immunity 12(2): 211-21. Haggarty, S. J., K. M. Koeller, et al. (2003). 'Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.' Proc Natl Acad Sci U S A 100(8): 4389-94. Hanahan, D. and R. A. Weinberg (2000). 'The hallmarks of cancer.' Cell 100(1): 57-70. Hansen, T. H., S. Huang, et al. (2007). 'Patterns of nonclassical MHC antigen presentation.' Nat Immunol 8(6): 563-8. Hayakawa, Y., K. Takeda, et al. (2001). 'Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.' Eur J Immunol 31(6): 1720-7. Horiuchi, J., N. Silverman, et al. (1995). 'ADA3, a putative transcriptional adaptor, consists of two separable domains and interacts with ADA2 and GCN5 in a trimeric complex.' Mol Cell Biol 15(3): 1203-9. Hu, E., E. Dul, et al. (2003). 'Identification of novel isoform-selective inhibitors within class I histone deacetylases.' J Pharmacol Exp Ther 307(2): 720-8. Jabbour, E. J. and F. J. Giles (2005). 'New agents in myelodysplastic syndromes.' Curr Hematol Rep 4(3): 191-9. Johnstone, R. W. (2002). 'Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.' Nat Rev Drug Discov 1(4): 287-99. Kawano, T., J. Cui, et al. (1997). 'CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.' Science 278(5343): 1626-9. Kawano, T., J. Cui, et al. (1998). 'Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.' Proc Natl Acad Sci U S A 95(10): 5690-3. Kawano, T., T. Nakayama, et al. (1999). 'Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells.' Cancer Res 59(20): 5102-5. Kelly, W. K. and P. A. Marks (2005). 'Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.' Nat Clin Pract Oncol 2(3): 150-7. Kelly, W. K., O. A. O'Connor, et al. (2002). 'Histone deacetylase inhibitors: from target to clinical trials.' Expert Opin Investig Drugs 11(12): 1695-713. Kinjo, Y., D. Wu, et al. (2005). 'Recognition of bacterial glycosphingolipids by natural killer T cells.' Nature 434(7032): 520-5. Kinzler, K. W. and B. Vogelstein (1997). 'Cancer-susceptibility genes. Gatekeepers and caretakers.' Nature 386(6627): 761, 763. Kitamura, H., K. Iwakabe, et al. (1999). 'The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.' J Exp Med 189(7): 1121-8. Koch, M., V. S. Stronge, et al. (2005). 'The crystal structure of human CD1d with and without alpha-galactosylceramide.' Nat Immunol 6(8): 819-26. Kulp, S. K., C. S. Chen, et al. (2006). 'Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.' Clin Cancer Res 12(17): 5199-206. Leder, A., S. Orkin, et al. (1975). 'Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis.' Science 190(4217): 893-4. Lee, H. B., H. Noh, et al. (2007). 'Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.' Kidney Int Suppl(106): S61-6. Lin, Y. C., J. H. Lin, et al. (2008). 'Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.' Cancer Res 68(7): 2375-83. Lindemann, R. K., B. Gabrielli, et al. (2004). 'Histone-deacetylase inhibitors for the treatment of cancer.' Cell Cycle 3(6): 779-88. Liu, K., Y. F. Wang, et al. (2003). 'Endogenous assays of DNA methyltransferases: Evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo.' Mol Cell Biol 23(8): 2709-19. Loidl, P. (1994). 'Histone acetylation: facts and questions.' Chromosoma 103(7): 441-9. Lu, Q., Y. T. Yang, et al. (2004). 'Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors.' J Med Chem 47(2): 467-74. Lu, Y. S., Y. Kashida, et al. (2007). 'Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.' Hepatology 46(4): 1119-30. Lund, A. H. and M. van Lohuizen (2004). 'Epigenetics and cancer.' Genes Dev 18(19): 2315-35. Maeda, T., M. Towatari, et al. (2000). 'Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.' Blood 96(12): 3847-56. Magner, W. J., A. L. Kazim, et al. (2000). 'Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.' J Immunol 165(12): 7017-24. Marks, P., R. A. Rifkind, et al. (2001). 'Histone deacetylases and cancer: causes and therapies.' Nat Rev Cancer 1(3): 194-202. Marks, P. A. (2007). 'Discovery and development of SAHA as an anticancer agent.' Oncogene 26(9): 1351-6. Marks, P. A. and X. Jiang (2005). 'Histone deacetylase inhibitors in programmed cell death and cancer therapy.' Cell Cycle 4(4): 549-51. Marks, P. A., T. Miller, et al. (2003). 'Histone deacetylases.' Curr Opin Pharmacol 3(4): 344-51. Marks, P. A., V. M. Richon, et al. (2000). 'Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.' J Natl Cancer Inst 92(15): 1210-6. Marks, P. A. and R. A. Rifkind (1978). 'Erythroleukemic differentiation.' Annu Rev Biochem 47: 419-48. Marks, P. A., M. Sheffery, et al. (1987). 'Induction of transformed cells to terminal differentiation and the modulation of gene expression.' Cancer Res 47(3): 659-66. Mattner, J., K. L. Debord, et al. (2005). 'Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.' Nature 434(7032): 525-9. Mendiratta, S. K., W. D. Martin, et al. (1997). 'CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4.' Immunity 6(4): 469-77. Michaelis, M., U. R. Michaelis, et al. (2004). 'Valproic acid inhibits angiogenesis in vitro and in vivo.' Mol Pharmacol 65(3): 520-7. Miyamoto, K., S. Miyake, et al. (2001). 'A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.' Nature 413(6855): 531-4. Morita, M., K. Motoki, et al. (1995). 'Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice.' J Med Chem 38(12): 2176-87. Motohashi, S., S. Kobayashi, et al. (2002). 'Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.' Int J Cancer 102(2): 159-65. Nakagawa, R., I. Nagafune, et al. (2001). 'Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.' J Immunol 166(11): 6578-84. Nelson, J. D., O. Denisenko, et al. (2006). 'Protocol for the fast chromatin immunoprecipitation (ChIP) method.' Nat Protoc 1(1): 179-85. Nightingale, K. P., L. P. O'Neill, et al. (2006). 'Histone modifications: signalling receptors and potential elements of a heritable epigenetic code.' Curr Opin Genet Dev 16(2): 125-36. Nusinzon, I. and C. M. Horvath (2003). 'Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1.' Proc Natl Acad Sci U S A 100(25): 14742-7. Owen-Hughes, T. and J. L. Workman (1994). 'Experimental analysis of chromatin function in transcription control.' Crit Rev Eukaryot Gene Expr 4(4): 403-41. Pandolfi, P. P. (2001). 'Histone deacetylases and transcriptional therapy with their inhibitors.' Cancer Chemother Pharmacol 48 Suppl 1: S17-9. Peart, M. J., K. M. Tainton, et al. (2003). 'Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.' Cancer Res 63(15): 4460-71. Qian, D. Z., Y. Kato, et al. (2006). 'Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.' Clin Cancer Res 12(2): 634-42. Reddy, P., Y. Maeda, et al. (2004). 'Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.' Proc Natl Acad Sci U S A 101(11): 3921-6. Renukaradhya, G. J., T. J. Webb, et al. (2005). 'Virus-induced inhibition of CD1d1-mediated antigen presentation: reciprocal regulation by p38 and ERK.' J Immunol 175(7): 4301-8. Richon, V. M., S. Emiliani, et al. (1998). 'A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.' Proc Natl Acad Sci U S A 95(6): 3003-7. Richon, V. M., R. G. Ramsay, et al. (1989). 'Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation.' Oncogene 4(2): 165-73. Richon, V. M., Y. Webb, et al. (1996). 'Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.' Proc Natl Acad Sci U S A 93(12): 5705-8. Riggs, M. G., R. G. Whittaker, et al. (1977). 'n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells.' Nature 268(5619): 462-4. Roth, S. Y., J. M. Denu, et al. (2001). 'Histone acetyltransferases.' Annu Rev Biochem 70: 81-120. Ruefli, A. A., M. J. Ausserlechner, et al. (2001). 'The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.' Proc Natl Acad Sci U S A 98(19): 10833-8. Salamone, M. C., G. A. Rabinovich, et al. (2001). 'Activation-induced expression of CD1d antigen on mature T cells.' J Leukoc Biol 69(2): 207-14. Sanchez, D. J., J. E. Gumperz, et al. (2005). 'Regulation of CD1d expression and function by a herpesvirus infection.' J Clin Invest 115(5): 1369-78. Sargeant, A. M., R. C. Rengel, et al. (2008). 'OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.' Cancer Res 68(10): 3999-4009. Sasakawa, Y., Y. Naoe, et al. (2003). 'Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.' Biochem Pharmacol 66(6): 897-906. Schmieg, J., G. Yang, et al. (2003). 'Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide.' J Exp Med 198(11): 1631-41. Seino, K., S. Motohashi, et al. (2006). 'Natural killer T cell-mediated antitumor immune responses and their clinical applications.' Cancer Sci 97(9): 807-12. Shimizu, K., A. Goto, et al. (2007). 'Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.' J Immunol 178(5): 2853-61. Shimizu, K., Y. Kurosawa, et al. (2007). 'Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells.' J Exp Med 204(11): 2641-53. Skold, M. and S. M. Behar (2003). 'Role of CD1d-restricted NKT cells in microbial immunity.' Infect Immun 71(10): 5447-55. Skold, M., X. Xiong, et al. (2005). 'Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell activation.' J Immunol 175(6): 3584-93. Skov, S., M. T. Pedersen, et al. (2005). 'Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.' Cancer Res 65(23): 11136-45. Smyth, M. J., E. Cretney, et al. (2001). 'Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.' J Exp Med 193(6): 661-70. Smyth, M. J., N. Y. Crowe, et al. (2001). 'NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.' Int Immunol 13(4): 459-63. Smyth, M. J., N. Y. Crowe, et al. (2002). 'Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.' Blood 99(4): 1259-66. Smyth, M. J., K. Y. Thia, et al. (2000). 'Differential tumor surveillance by natural killer (NK) and NKT cells.' J Exp Med 191(4): 661-8. Sowa, Y., T. Orita, et al. (1997). 'Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.' Biochem Biophys Res Commun 241(1): 142-50. Sriram, V., S. Cho, et al. (2002). 'Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells.' Proc Natl Acad Sci U S A 99(12): 8197-202. Steger, D. J. and J. L. Workman (1996). 'Remodeling chromatin structures for transcription: what happens to the histones?' Bioessays 18(11): 875-84. Strahl, B. D. and C. D. Allis (2000). 'The language of covalent histone modifications.' Nature 403(6765): 41-5. Street, S. E., Y. Hayakawa, et al. (2004). 'Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells.' J Exp Med 199(6): 879-84. Stronge, V. S., M. Salio, et al. (2007). 'A closer look at CD1d molecules: new horizons in studying NKT cells.' Trends Immunol 28(10): 455-62. Swann, J., N. Y. Crowe, et al. (2004). 'Regulation of antitumour immunity by CD1d-restricted NKT cells.' Immunol Cell Biol 82(3): 323-31. Tahir, S. M., O. Cheng, et al. (2001). 'Loss of IFN-gamma production by invariant NK T cells in advanced cancer.' J Immunol 167(7): 4046-50. Terabe, M. and J. A. Berzofsky (2007). 'NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis.' Trends Immunol 28(11): 491-6. Thiagalingam, S., K. H. Cheng, et al. (2003). 'Histone deacetylases: unique players in shaping the epigenetic histone code.' Ann N Y Acad Sci 983: 84-100. Tomura, M., W. G. Yu, et al. (1999). 'A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.' J Immunol 163(1): 93-101. Tsankova, N., W. Renthal, et al. (2007). 'Epigenetic regulation in psychiatric disorders.' Nat Rev Neurosci 8(5): 355-67. Tsuneyama, K., M. Yasoshima, et al. (1998). 'Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis.' Hepatology 28(3): 620-3. Ulanova, M., M. Torebring, et al. (2000). 'Expression of CD1d in the duodenum of patients with cow's milk hypersensitivity.' Scand J Immunol 52(6): 609-17. Wang, H., Y. Zhao, et al. (2008). 'An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment.' J Biol Chem 283(5): 2564-74. Warrener, R., H. Beamish, et al. (2003). 'Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints.' Faseb J 17(11): 1550-2. Wu, D. Y., N. H. Segal, et al. (2003). 'Cross-presentation of disialoganglioside GD3 to natural killer T cells.' J Exp Med 198(1): 173-81. Xiong, Z. and P. W. Laird (1997). 'COBRA: a sensitive and quantitative DNA methylation assay.' Nucleic Acids Res 25(12): 2532-4. Yanagisawa, K., K. Seino, et al. (2002). 'Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide.' J Immunol 168(12): 6494-9. Yoo, C. B., J. C. Cheng, et al. (2004). 'Zebularine: a new drug for epigenetic therapy.' Biochem Soc Trans 32(Pt 6): 910-2. Yoshida, M., M. Kijima, et al. (1990). 'Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.' J Biol Chem 265(28): 17174-9. Yuan, W., A. Dasgupta, et al. (2006). 'Herpes simplex virus evades natural killer T cell recognition by suppressing CD1d recycling.' Nat Immunol 7(8): 835-42. Yuan, Z. L., Y. J. Guan, et al. (2005). 'Stat3 dimerization regulated by reversible acetylation of a single lysine residue.' Science 307(5707): 269-73. Zajonc, D. M., C. Cantu, 3rd, et al. (2005). 'Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor.' Nat Immunol 6(8): 810-8. Zhou, D., J. Mattner, et al. (2004). 'Lysosomal glycosphingolipid recognition by NKT cells.' Science 306(5702): 1786-9. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37904 | - |
| dc.description.abstract | 本論文探討新穎抗癌藥物，HDAC抑制劑引發CD1d表現與其免疫調節之功能。在A549和TC-1細胞，TSA和SAHA引發dose-及time-dependent之CD1d表現，進一步探討TSA誘導CD1d mRNA表現之機轉，A549及TC-1細胞預先處理PKC抑制劑Ro318220、ROCK抑制劑Y27632、CaM kinase II抑制劑KN-62、p38抑制劑SB203580、MEK抑制劑PD98059、JNK抑制劑SP600125、PI3K抑制劑LY294002、mTOR抑制劑rapamycin、Akt抑制劑SH-5或PI3K抑制劑wortmannin，皆不影響TSA所誘導之CD1d mRNA表現。Sp1抑制劑MTM可阻斷SAHA所誘導的CD1d mRNA表現及Sp1 luciferase和RARE3-tk-luciferase reporter活性。將GAL4-Sp1及Fc-luciferase reporter同時transfect至A549細胞，發現HDAC抑制劑是經由增加Sp1 transactivation活性促進Sp1之reporter活性。ChIP實驗證明，HDAC抑制劑會增加Sp1與乙醯化histone-H3結合至CD1d啟動子。將TC-1細胞與C57BL/6小鼠之脾臟細胞共同培養，HDAC抑制劑所誘導表現之CD1d蛋白，可呈現glycolipid給NKT細胞，使之活化增加IFN-γ釋放，但降低IL-4之釋放。DNMT抑制劑會促進HDAC抑制劑增加CD1d之mRNA與蛋白表現；HDAC6抑制劑tubacin不影響CD1d之mRNA，但增加膜上蛋白之表現。 | zh_TW |
| dc.description.abstract | We investigate the effect of novel anticancer drugs, HDAC inhibitors on CD1d expression in tumor cells, and the related immune regulation. TSA and SAHA were found to induce CD1d expression in a dose- and time-dependent manner in A549 ( human lung adenocarcinoma cell line) and TC-1 ( mouse lung cancer cell line) cells. TSA-induced CD1d was not blocked by the pre-treatment with PKC inhibitor (Ro318220)、ROCK inhibitor (Y27632)、CaM kinase II inhibitor (KN-62)、p38 inhibitor (SB203580)、MEK inhibitor PD98059、JNK inhibitor (SP600125)、PI3K inhibitor (LY294002)、mTOR inhibitor (rapamycin)、Akt inhibitor (SH-5) or PI3K inhibitor (wortmannin). However, Sp1 inhibitor MTM blocked the CD1d mRNA expression, Sp1 luciferase and RARE3-tk-luciferase reporter activity induced by SAHA. Co-transfection of GAL4-Sp1 and Fc-luciferase reporter demonstrated that HDAC inhibitor induced Sp1 luciferase reporter activity by enhancing Sp1 transactivation activity. The binding of Sp1 and acetylated histone-H3 to CD1d promoter was increased by HDAC inhibitors. Co-culture of C57BL/6 splenocytes with SAHA-treated TC-1 cells showed the presentation of glycolipid to the splenocytes, resulting in the increased secretion of IFN-γ and decreased secretion of IL-4. DNMT inhibitor, Zebularine promoted the CD1d induction by HDAC inhibitor. HDAC6 inhibitor, tubacin induced CD1d protein but not mRNA expression. In summary, these results indicate that HDAC inhibitors could up-regulate CD1d expression in tumor cells, and tumor/glycolipid are effective for IFN-γ secretion by splenocytes to exert possible anti-tumor activity. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T15:50:16Z (GMT). No. of bitstreams: 1 ntu-97-R95443009-1.pdf: 3132752 bytes, checksum: 85342bafe6820eb42c3c63c11dae7527 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 縮寫表……………………………………………………………… I
(Abbreviation) 中文摘要…………………………………………………………… IV (Abstract in Chinese) 英文摘要…………………………………………………………… V (Abstract in English) 緒論………………………………………………………………… 1 (Introduction) 實驗材料與方法……………………………………………………25 (Materials and Methods) 結果…………………………………………………………………37 (Results) 討論…………………………………………………………………64 (Discussion) 參考文獻……………………………………………………………73 (References) | |
| dc.language.iso | zh-TW | |
| dc.subject | CD1d | zh_TW |
| dc.subject | 組織蛋白去乙醯酶 | zh_TW |
| dc.subject | HDAC inhibitors | en |
| dc.subject | CD1d | en |
| dc.title | 組織蛋白去乙醯酶抑制劑誘發CD1d表現之研究 | zh_TW |
| dc.title | Investigation of HDAC Inhibitors-induced CD1d Expression | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳明賢(Ming-Shiang Wu),李建國(Chien-Kuo Lee) | |
| dc.subject.keyword | 組織蛋白去乙醯酶,CD1d, | zh_TW |
| dc.subject.keyword | HDAC inhibitors,CD1d, | en |
| dc.relation.page | 83 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2008-06-26 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 未授權公開取用 | 3.06 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。